Results 111 to 120 of about 15,943 (150)

Steroid-sparing strategies for managing immune-related adverse events. [PDF]

J Immunother Cancer
Huang JJ, YousefiAsl M, Singh N, Grivas P, Bhatia S.   +4 more
europepmc   +1 more source

Do we need to treat dialysis patients differently? Infliximab therapy in a patient with ulcerative colitis on hemodialysis: a case report. [PDF]

J Med Case Rep
Balogh F, Angyal D, Gonczi L, Lontai L, Lakatos PL, Ilias A.   +5 more
europepmc   +1 more source

Case Report: Severe kidney involvement in a case of very early onset inflammatory bowel disease. [PDF]

Front Immunol
Drago E, Carfora R, Cafferata B, Gaggero G, Puzone L, La Porta E, Signa S, Gandullia P, Vellone VG, Angeletti A, Arrigo S.   +10 more
europepmc   +1 more source

Esophageal Crohn's Disease Successfully Treated With Risankizumab. [PDF]

ACG Case Rep J
Hallcox T, Stein D.
europepmc   +1 more source

Dual biologic therapy in patient with refractory ulcerative colitis and comorbidities: A case report. [PDF]

World J Gastroenterol
Guimarães AC, Ferreiro-Iglesias R, Calviño-Suarez C, Baston-Rey I, Barreiro-de Acosta M.   +4 more
europepmc   +1 more source

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease. [PDF]

Contemp Clin Trials Commun
Danese S, Sands BE, Feagan BG, Jairath V, Panaccione R, Peyrin-Biroulet L, Irving PM, Schreiber S, Dotan I, Ferrante M, D'Haens GR, Jones S, Freire M, Lindner D, Adsul S, Oberai P, Colombel JF.   +16 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain. [PDF]

Pharmacoecon Open
Rodríguez-Lago I, Muñoz Núñez F, Lucendo AJ, De Lossada Juste A, Cabez A, de la Cuadra-Grande A, Oyagüez I, Monte-Boquet E.   +7 more
europepmc   +1 more source

Advanced Medical Therapies for Perianal Fistulizing Crohn's Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes. [PDF]

Pharmaceuticals (Basel)
Jamal F, Segun-Omosehin T, Viggiano T, Khan H, Gonzalez AJ, Thomas G, Elmasry S, Malik TA.   +7 more
europepmc   +1 more source

Pharmacovigilance study of adverse events of vedolizumab based on the FAERS database. [PDF]

Sci Rep
Yuan G, Liu J, Xu Y, Shan Z.
europepmc   +1 more source